LG Chem joins in the 3-way race in Humira biosimilar mkt
By Chon, Seung-Hyun | translator Kim, Jung-Ju
23.12.15 12:01:15
가나다라
0
LG Chem’s Humira biosimilar, Xelenka, is approved...3rd company to receive approval after Samsung and Celltrion
Biosimilar’s share in Humira market in Q3 reaches 15%...original drug still exerts a strong influence over the market
Humira’s drug price was reduced with the release of biosimilars… contributed to NHI financial savings
LG Chem has joined in to compete for a share of the Humira biosimilar market. Humira is an original autoimmune disease treatment. With the introduction, a three-way competition will start between Samsung Bioepis, Celltrion, and LG Chem in the KRW 100 billion annual market. It has been 2 years since biosimilars entered the Humira market, but the original product still has a stronghold and remains unrivaled in the market.
LG Chem announced on the 15th that it has received marketing authorization from the Ministry of Food and Drug Safety for its adalimumab Humira biosimilar Xelenka. Two types of Xelenka - Xelenka Prefilled Syringe Inj and Xelenka Autoinjector Inj – were approved at the time.
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)